IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

執行長

Mr. Andrew Hall M.Sc.

員工

國家

ISIN

CA44974L3011

上市

0 Comments

分享你的想法

FAQ

IMV 今天的股價是多少？▼

IMV.TO 目前價格為 C$1.12 CAD，過去 24 小時下跌了 -1.75%。在圖表上更密切關注 IMV 股票的表現。

IMV 的股票代號是什麼？▼

根據交易所不同，股票代號可能會有所差異。例如，在交易所，IMV 的股票以代號 IMV.TO 進行交易。

IMV 去年的營收是多少？▼

IMV 去年的營收為 0CAD。

IMV 去年的淨利是多少？▼

IMV.TO 去年的淨收益為 -49.9MCAD。

IMV 有多少名員工？▼

截至 April 01, 2026，公司共有 97 名員工。

IMV 位於哪個產業？▼

IMV從事於Healthcare產業。

IMV 何時完成拆股？▼

IMV 最近沒有進行任何拆股。

IMV 的總部在哪裡？▼

IMV 的總部位於 CA 的 Dartmouth。